Novelties in the treatment of community-acquired and hospital-acquired pneumonia
Matteo Bassetti , Silvia Dettori , Federica Briano , Laura Mezzogori
*Correspondence: Federica Briano, Email not available
Abstract
Pneumonia remains a leading cause of morbidity and mortality worldwide, placing a significant burden on healthcare systems due to hospitalizations and the demand for medical resources. In recent years, new drugs have been developed to improve the effectiveness and safety of empirical treatment for community-acquired pneumonia and both empirical and targeted treatments for hospital-acquired and ventilator-associated pneumonia, including those caused by highly antibiotic-resistant pathogens. The aim of this narrative review is to focus on recently approved drugs for pneumonia and provide an overview of promising future therapeutic options.
